Congress Passes Bills Aimed at Boosting Generics and Biosimilars

Congress has sent President Biden two bills to boost generic and biosimilar drugs. Generics are exact copies and biosimilars are highly similar to original brand products. | Shutterstock

UPDATED Monday, April 26, 2021, 9:00 a.m. EDT—President Biden signed the two bills into law on April 23.

The U.S. House of Representatives passed two bills last week intended to reduce the overall costs of medications by boosting competition for

Read More »

BREAKING: Key GOP U.S. Senator Presses HHS Deputy Secretary Nominee to Take Action on 340B

Andrea Palm, President Biden's pick to be HHS Deputy Secretary, indicated in response to a question during her confirmation hearing today that "there are things [HHS] can and needs to be doing" about 340B hospitals' complaints about drugs manufacturers and PBMs.

Andrea Palm, President Biden’s pick to be the number two official at the U.S. Health and Human Services Department (HHS), pledged during her U.S. Senate confirmation hearing this morning to make sure that the 340B program “is working as it

Read More »

Could Concern About Hospital Price Transparency Boost Push for More Hospital 340B Transparency?

Bipartisan concern in Congress about hospitals' compliance with new price transparency rules might enhearten drugmakers and others who want to impose reporting requirements on 340B hospitals. | Shutterstock

The bipartisan leaders of the U.S. House Energy and Commerce (E&C) Committee and its Health Subcommittee wrote to U.S. Health and Human Services (HHS) Secretary Xavier Becerra this week asking him to enforce “full compliance” with the Trump administration’s hospital

Read More »

340B Could Come Up During Congressional Hearings Thursday

From left to right, HHS Secretary Xavier Becerra, CMS Administrator nominee Chiquita Brooks-LaSure, and HHS Deputy Secretary nominee Andrea Palm will all be on Capitol Hill on Thursday.

The U.S. Senate Finance Committee is scheduled to hold a hearing Thursday morning on President Biden’s nominations of Chiquita Brooks-LaSure to run the U.S. Centers for Medicare & Medicaid Services, and Andrea Palm to be U.S. Health and Human Services

Read More »

MACPAC Backs Medicaid Change That Could Lower Some 340B Prices

Raising the Medicaid rebate percentage and inflation penalty on accelerated-approval drugs, as the Medicaid and CHIP Payment and Access Commission (MACPAC) recommends, could lead to lower 340B ceiling prices on those drugs.

Congressional Medicaid policy advisers voted Friday to recommend raising the Medicaid rebate percentage and inflation penalty on drugs that are quickly and conditionally approved to treat serious conditions that fill an unmet need.

If Congress follows the Medicaid and CHIP

Read More »

NY State 340B Providers Get More Time to Challenge Reimbursement Change

New York lawmakers and Gov. Andrew Cuomo agreed on budget legislation this week that will delay a Medicaid drug benefit transfer opposed by 340B entities for two years.

New York state lawmakers and Gov. Andrew Cuomo (D) agreed this week to postpone transferring Medicaid managed care prescription drug  benefits to Medicaid fee for service (FFS) for two years, temporarily averting a significant financial loss to 340B covered entities.

Read More »

AHA Warns MedPAC its Recommendations Would Harm 340B Hospitals

Hospitals say that Medicare Part B drug reimbursement changes that MedPAC endorsed last week would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018. | Shutterstock

Congressional Medicare policy advisers on Friday unanimously endorsed Medicare Part B drug reimbursement changes that hospitals say would amplify the effect of Part B drug payment cuts for 340B hospitals in place since 2018.

The Medicare Payment Advisory Commission (MedPAC)

Read More »

340B Gets Cameo Role in Senate Hearing on Government Drug Price Negotiation

Harvard Medical School professor Dr. Aaron Kesselheim told a Senate subcommittee yesterday, “There’s no doubt the fact that 340B pricing is among the best prices we offer for certain high-cost drugs.”

The Senate committee with direct jurisdiction over the 340B program held its first drug pricing hearing of the 117th Congress Tuesday. It held the session amid signs that House Democrats want to add language to let Medicare negotiate drug prices

Read More »

Drug Pricing Is Heating Up in Congress Again

Sen. Bernie Sanders (I-Vt.) chaired today's Senate HELP subcommittee hearing on why the United States pays the highest prices in the world for prescription drugs.

A few years ago, there was hope that congressional Democrats and Republicans and the Trump administration would unite and enact legislation addressing the high price of prescription drugs.

It never happened. House Democrats passed a far-ranging drug pricing bill in

Read More »

Becerra Expected To Usher in Sea Change to 340B Governance

With Xavier Becerra in place as HHS secretary, 340B providers are hopeful he will act fast and decisively against drug manufacturers that have either stopped providing 340B discounts or placed restrictions on 340B pricing in the contract pharmacy setting. | Shutterstock

Updated, Friday, March 19, 9:30 a.m. EDT—After what initially appeared to be a rocky path to confirmation and a deadlocked vote in the U.S. Senate Finance Committee, California Attorney General Xavier Becerra (D) was confirmed today, by a 50-49 vote,

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live